Solasia Pharma K.K. (TYO:4597)

Market Cap	8.89B +10.1%
Revenue (ttm)	429.00M +35.8%
Net Income	-876.00M
EPS	-3.69
Shares Out	269.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,859,500
Average Volume	36,959,030
Open	32.00
Previous Close	33.00
Day's Range	32.00 - 35.00
52-Week Range	27.00 - 48.00
Beta	1.17
RSI	54.75
Earnings Date	May 13, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 23
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4597

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.